Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong & Laurent Peyrin-Biroulet. (2021) Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13:1.
Read now
Read now
Dae Hyun Yoo, Jung-Yoon Choe, Seung Cheol Shim & Chang-Hee Suh. (2018) Switching to biosimilars in the treatment of rheumatic diseases. Expert Review of Clinical Immunology 14:7, pages 557-571.
Read now
Read now
Dae Hyun Yoo. (2017) CT-P13 in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 13:7, pages 653-666.
Read now
Read now
J. Braun & J. Kay. (2017) The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety 16:3, pages 289-302.
Read now
Read now
Articles from other publishers (28)
Somenath Das & Anand Kumar Chaudhari. (2023) A review on the efficacy of essential oils and their nanoencapsulated formulations against aflatoxins contamination of major cereals with emphasis on mode of action. Biocatalysis and Agricultural Biotechnology 53, pages 102861.
Crossref
Crossref
Martin Toul, Veronika Slonkova, Jan Mican, Adam Urminsky, Maria Tomkova, Erik Sedlak, David Bednar, Jiri Damborsky, Lenka Hernychova & Zbynek Prokop. (2023) Identification, characterization, and engineering of glycosylation in thrombolytics. Biotechnology Advances 66, pages 108174.
Crossref
Crossref
Heather Myler, João Pedras-Vasconcelos, Todd Lester, Francesca Civoli, Weifeng Xu, Bonnie Wu, Inna Vainshtein, Linlin Luo, Mohamed Hassanein, Susana Liu, Swarna Suba Ramaswamy, Johanna Mora, Jason Pennucci, Fred McCush, Amy Lavelle, Darshana Jani, Angela Ambakhutwala, Daniel Baltrukonis, Breann Barker, Rebecca Carmean, Shan Chung, Sheng Dai, Stephen DeWall, Sanjay L. Dholakiya, Robert Dodge, Deborah Finco, Haoheng Yan, Amanda Hays, Zheng Hu, Cynthia Inzano, Lynn Kamen, Ching-Ha Lai, Erik Meyer, Robert Nelson, Amrit Paudel, Kelli Phillips, Marie-Eve Poupart, Qiang Qu, Mohsen Rajabi Abhari, Janka Ryding, Curtis Sheldon, Franklin Spriggs, Dominic Warrino, Yuling Wu, Lin Yang & Stephanie Pasas-Farmer. (2023) Neutralizing Antibody Validation Testing and Reporting Harmonization. The AAPS Journal 25:4.
Crossref
Crossref
Scott P. HenryCecilia ArfvidssonJosh ArringtonJasna CanadiDave Crowe, Shalini GuptaSabine LohmannBenoit MassonnetDaniel MytychTina RogersHobart RogersChris StebbinsCraig StovoldDaniela VerthelyiAdam Vigil, Chi XuanYuanxin XuRosie YuThomas Klem. (2022) Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs. Nucleic Acid Therapeutics 32:5, pages 369-377.
Crossref
Crossref
Jinlu Zhang, Linlin Hu & Hua Shao. (2022) Research Progress on Quantification Methods of Drug Concentration of
Monoclonal Antibodies. Current Pharmaceutical Analysis 18:7, pages 663-676.
Crossref
Crossref
Kyungah Suh, Isaac Kyei & David S. Hage. (2022) Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review. Journal of Separation Science 45:12, pages 2077-2092.
Crossref
Crossref
Ramandeep Singh, Rohan Chauhan, Ashish Saxena, Anup Shah, Laxshmi Mondal, Dhananjay Bakhle, Chirag Shah, Arpit Shah, Shashank Deoghare, Neelakant Krishnan & Neelima Godse. (2022)
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis
®
in patients with neovascular age-related macular degeneration
. Indian Journal of Ophthalmology 70:8, pages 3008.
Crossref
Crossref
Abdoulie Jallow, Huali Xie, Xiaoqian Tang, Zhang Qi & Peiwu Li. (2021) Worldwide aflatoxin contamination of agricultural products and foods: From occurrence to control. Comprehensive Reviews in Food Science and Food Safety 20:3, pages 2332-2381.
Crossref
Crossref
Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier, Yann G. J. Sterckx, Sofie Denies, Benoit Stijlemans, Yvon Elkrim, Nick Devoogdt, Vicky Caveliers, Tony Lahoutte, Serge Muyldermans, Karine Breckpot & Marleen Keyaerts. (2021) Immunogenicity Risk Profile of Nanobodies. Frontiers in Immunology 12.
Crossref
Crossref
Robert J. Flanagan, Eva Cuypers, Hans H. Maurer & Robin Whelpton. 2020. Fundamentals of Analytical Toxicology. Fundamentals of Analytical Toxicology
145
166
.
Gregor Jordan & Roland F Staack. (2020) Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody–reagent complexes at cut-point (CP-ARC) the missing piece?. Bioanalysis 12:14, pages 1021-1031.
Crossref
Crossref
Johanna R Mora, Joleen T White, Shannon D Chilewski, Qiang Qu, Dennis Stocker, Linlin Luo & Amy Lavelle. (2020) Strategies for method comparison when changes in the immunogenicity method are needed within a clinical program. Bioanalysis 12:7, pages 431-443.
Crossref
Crossref
HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese & Ji Hoon Jeong. (2020) The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80:2, pages 99-113.
Crossref
Crossref
Vibeke Strand, Joao Gonçalves, Timothy P. Hickling, Heather E. Jones, Lisa Marshall & John D. Isaacs. (2019) Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. BioDrugs 34:1, pages 27-37.
Crossref
Crossref
Gloria S. Z. Tun, Robert Downey, Kerry Robinson, Alison Wright, Laura Marshall, Kristina Emsell, Kirsty Swallow, Graeme Wild, Alenka J. Brooks, Thean S. Chew, Melissa F. Hale, Ravishankar Sargur & Alan J. Lobo. (2019) High prevalence of antibodies to infliximab and their relation to clinical outcomes in inflammatory bowel disease patients. GastroHep 1:5, pages 214-222.
Crossref
Crossref
Vladimir V. KlimovVladimir V. Klimov. 2019. From Basic to Clinical Immunology. From Basic to Clinical Immunology
217
235
.
Lieke Tweehuysen, Victor J. B. Huiskes, Bart J. F van den Bemt, Johanna E. Vriezekolk, Steven Teerenstra, Frank H. J. van den Hoogen, Cornelia H. van den Ende & Alfons A. den Broeder. (2018) Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4. Arthritis & Rheumatology 70:9, pages 1408-1418.
Crossref
Crossref
Wenfang S. Wu, Liang Zhu, Saurabh Patil, Karthiga Gokul, Sean Reilly, Joyce Chan, Poornima Tekumalla, Vivek Vishnudas, Michael A. Kiebish, Rangaprasad Sarangarajan, Viatcheslav R. Akmaev, Mark D. Kellogg & Niven R. Narain. (2018) Human CCDC47 sandwich immunoassay development with electrochemiluminescence technology. Journal of Immunological Methods 452, pages 12-19.
Crossref
Crossref
Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini & Meenu Wadhwa. (2018) Reprint of “Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab”. Cytokine 101, pages 70-77.
Crossref
Crossref
Cong-Qiu Chu. (2018) How much have we learnt about the TNF family of cytokines?. Cytokine 101, pages 1-3.
Crossref
Crossref
Paul Chamberlain & Pekka Kurki. 2018. Biosimilars. Biosimilars
489
542
.
Dae Hyun Yoo. (2017) Comparative effectiveness of the biosimilar CT-P13. Journal of Comparative Effectiveness Research 6:8, pages 693-712.
Crossref
Crossref
Niels Vande Casteele. (2017) Assays for measurement of TNF antagonists in practice. Frontline Gastroenterology 8:4, pages 236-242.
Crossref
Crossref
Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini & Meenu Wadhwa. (2017) Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 96, pages 16-23.
Crossref
Crossref
Walter Reinisch, Jørgen Jahnsen, Stefan Schreiber, Silvio Danese, Julián Panés, Alejandro Balsa, Won Park, JiSoo Kim, Jee Un Lee & Dae Hyun Yoo. (2017) Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. BioDrugs 31:3, pages 223-237.
Crossref
Crossref
Dae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, Slawomir Jeka, Francisco Fidencio Cons-Molina, Pawel Hrycaj, Piotr Wiland, Eun Young Lee, Francisco G Medina-Rodriguez, Pavel Shesternya, Sebastiao Radominski, Marina Stanislav, Volodymyr Kovalenko, Dong Hyuk Sheen, Leysan Myasoutova, Mie Jin Lim, Jung-Yoon Choe, Sang Joon Lee, Sung Young Lee, Taek Sang Kwon & Won Park. (2017) A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 76:3, pages 566-570.
Crossref
Crossref
Christina Y. Ha & Asher Kornbluth. (2016) A Critical Review of Biosimilars in IBD. Inflammatory Bowel Diseases 22:10, pages 2513-2526.
Crossref
Crossref
Eszter Lázár-Molnár & Julio C Delgado. (2016) Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory. Clinical Chemistry 62:9, pages 1186-1198.
Crossref
Crossref